ABP 215
ABP 215 (Bevacizumab-awwb), a Bevacizumab biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA. ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research[1][2].
Product Specifications
CAS Number
1438851-35-4
UNSPSC
12352203
Target
VEGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/abp-215.html
Solubility
10 mM in DMSO
Smiles
[ABP215]
References & Citations
[1]Neungseon Seo, et al. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs. 2018 May/Jun;10 (4) :678-691. |[2]Whitney Rhodes, et al. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. Future Oncol. 2021 Dec;17 (36) :5119-5127.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog